Business Wire

LEO Pharma announces FDA approval of Adbry™ (tralokinumab-ldrm) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis

MADISON, N.J.--(BUSINESS WIRE)--LEO Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Adbry ™ (tralokinumab-ldrm) for the treatment of moderate-to-severe atopic ...
WebMD

Adbry for Atopic Dermatitis: What You Need to Know

If you have atopic dermatitis, a skin condition commonly known as eczema, prescription creams or other topical medicines and moisturizers are usually enough to manage it. However, if your eczema is ...
Business Wire

LEO Pharma Presents New Interim Long-Term Efficacy Data for Adbry™ (tralokinumab-ldrm) in Moderate-to-Severe Atopic Dermatitis at the 2022 RAD Conference

Interim post-hoc efficacy analysis from ECZTEND, an open-label, 5-year extension trial, showed long-term improvements in extent and severity of atopic dermatitis and itch in a subgroup of adult ...
MarketWatch

LEO Pharma Presents Final Results of ECZTEND Long-Term Adbry(R) Trial (tralokinumab-ldrm) in Patients with Moderate-to-Severe Atopic Dermatitis (AD) at Fall Clinical 2024

The MarketWatch News Department was not involved in the creation of this content. LEO Pharma Presents Final Results of ECZTEND Long-Term Adbry(R) Trial (tralokinumab-ldrm) in Patients with Moderate-to ...
Monthly Prescribing Reference

Adbry Approved for Moderate to Severe Atopic Dermatitis

The approval was based on data from 3 pivotal phase 3 (ECZTRA 1-3) trials that evaluated the safety and efficacy of Adbry in 1934 adults with moderate to severe AD. The Food and Drug Administration ...
Monthly Prescribing Reference

Adbry Approval Expanded to Pediatric Patients with Atopic Dermatitis

Findings showed 21% of patients treated with tralokinumab achieved an IGA score of 0 or 1 at week 16 compared with 4% of those who received placebo. The Food and Drug Administration (FDA) has expanded ...